Hidemasa Ogawa

Title: Hidemasa Ogawa: Innovator in Antitumor Research

Introduction

Hidemasa Ogawa is a prominent inventor based in Tokyo, Japan. He has made significant contributions to the field of biomedical research, particularly in the development of compounds with potential antitumor properties. With a total of 4 patents to his name, Ogawa's work is recognized for its innovative approach to addressing critical health challenges.

Latest Patents

One of Ogawa's latest patents is focused on a sulfated polysaccharide known as DS4152. This compound is useful as an angiogenesis inhibitor or antitumor agent. The sodium salt of DS4152 exhibits specific physicochemical characteristics, including a molecular weight of approximately 29,000 ± 3,000. The elemental analysis reveals a composition of C: 24.42-25.76%, H: 3.34-3.98%, N: 0.51-0.89%, S: 10.6-11.7%, and P: 0.77-1.06%. Additionally, the sugar content is around 57 ± 3%, while the protein content is approximately 1 ± 0.5%. The specific rotatory power of the 0.5% aqueous solution is -37° ± 1°. The infrared absorption spectrum of DS4152 shows characteristic absorption bands at 1240, 840 (shoulder), and 810 cm⁻¹. Another notable patent involves mannoglucan derivatives, which demonstrate antitumor activity with reduced pyrogenicity.

Career Highlights

Hidemasa Ogawa is affiliated with Daiichi Seiyaku Co., Ltd., where he continues to advance his research. His work has garnered attention for its potential applications in cancer treatment and therapeutic development.

Collaborations

Ogawa has collaborated with notable colleagues, including Tetsuo Shiba and Shozo Kotani, to further enhance the impact of his research.

Conclusion

Hidemasa Ogawa's innovative contributions to antitumor research highlight his role as a leading inventor in the field. His patents reflect a commitment to developing effective therapeutic agents that could significantly benefit cancer treatment.